Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells

Pancreas

Volumn 38, Issue 5, 2009, Pages 551-557

  Wang, Hong ^a   Stephens, Bret ^a   Von Hoff, Daniel D ^a   Han, Haiyong ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

DPC4 deficiency; Drug discovery; Pancreatic cancer; Synthetic lethality

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN DEPENDENT KINASE 1; SMAD4 PROTEIN; UA 62784; UA 64436; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CLONOGENESIS; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; GENE DELETION; GENE LOCUS; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN B; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENOTYPE; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; OXAZOLES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; SMAD4 PROTEIN; TUMOR STEM CELL ASSAY; XANTHONES;

EID: 67651100613     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819d7415     Document Type: Article

References (38)

1. Hahn SA, Hoque AT, Moskaluk CA, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996;56:490-494.
2. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271: 350-353. (Pubitemid 3021510)
3. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res. 1996;56:2527-2530. (Pubitemid 26170688)
4. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet. 1996;13:343-346. (Pubitemid 26230501)
5. Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999;18:3098-3103. (Pubitemid 29261230)
6. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun. 2003;306:799-804. (Pubitemid 36776201)
7. Xie W, Mertens JC, Reiss DJ, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002;62:497-505. (Pubitemid 34106424)
8. Zhong D, Morikawa A, Guo L, et al. Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas. Cancer Biol Ther. 2006;5:601-607. (Pubitemid 44024713)
9. Luttges J, Galehdari H, Brocker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol. 2001;158:1677-1683. (Pubitemid 32422932)
10. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-2006. (Pubitemid 30207663)
11. Heinmoller E, Dietmaier W, Zirngibl H, et al. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol. 2000;157:83-92. (Pubitemid 30641727)
12. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295-309.
13. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A. 2000;97:9624-9629. (Pubitemid 30650826)
14. Raptopoulos V, Steer ML, Sheiman RG, et al. The use of helical CT and CTangiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. AJR Am J Roentgenol. 1997; 168:971-977. (Pubitemid 27146928)
15. Sunamura M, Oonuma M, Motoi F, et al. Gene therapy for pancreatic cancer targeting the genomic alterations of tumor suppressor genes using replication-selective oncolytic adenovirus. Hum Cell. 2002;15:138-150.
16. Sunamura M, Yatsuoka T, Motoi F, et al. Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg. 2002;9:32-38. (Pubitemid 34477368)
17. Pearson AS, Bouvet M, Evans DB, et al. Gene therapy and pancreatic cancer. Front Biosci. 1998;3:E230-E237.
18. Blagosklonny MV. P53: an ubiquitous target of anticancer drugs. Int J Cancer. 2002;98:161-166.
19. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5:689-698.
20. Gallmeier E, Calhoun ES, Rago C, et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology. 2006;130:2145-2154. (Pubitemid 43816948)
21. Turcotte S, Chan DA, Sutphin PD, et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008;14:90-102. (Pubitemid 351885499)
22. Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3: 285-296. (Pubitemid 37443883)
23. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234-245.
24. Wang H, Han H, Von Hoff DD. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res. 2006;66:9722-9730. (Pubitemid 44623673)
25. Ouyang H, Mou L, Luk C, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000;157:1623-1631. (Pubitemid 30943220)
26. Zhou S, Buckhaults P, Zawel L, et al. Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A. 1998;95:2412-2416. (Pubitemid 28145955)
27. Stephens B, Han H, Hostetter G, et al. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther. 2008;7:202-210.
28. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188-193.
29. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J. 1991;10:3321-3329. (Pubitemid 21905357)
30. Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278:1064-1068. (Pubitemid 27517876)
31. Simon JA, Szankasi P, Nguyen DK, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 2000;60:328-333. (Pubitemid 30070759)
32. Torrance CJ, Agrawal V, Vogelstein B, et al. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol. 2001;19:940-945. (Pubitemid 32947572)
33. Stockwell BR, Haggarty SJ, Schreiber SL. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem Biol. 1999;6:71-83.
34. Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov. 2005;4:461-467.
35. DiPaola RS, Rinehart J, Nemunaitis J, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol. 2002;20:1874-1879. (Pubitemid 34273279)
36. Shi L, Nishioka WK, Th'ng J, et al. Premature p34cdc2 activation required for apoptosis. Science. 1994;263:1143-1145.
37. Shen SC, Huang TS, Jee SH, et al. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ. 1998;9:23-29.
38. Shimizu T, O'Connor PM, Kohn KW, et al. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res. 1995;55:228-231.